Arcadia Biosciences, Inc.

Snapshot

Arcadia is a tiny consumer-products micro-cap (Zola coconut water) burning cash while its stock sits near its 52-week low. FY 2025 revenue was $4.9M, down 3.7%, with a $2.3M net loss.

What's Happening Right Now

• Tue 15th Sep '26 · Reverse split: Shareholders approved on September 10, 2026 a charter amendment letting the board carry out a 1-for-2 to 1-for-10 reverse stock split anytime before June 30, 2027 to address the sub-$1 share price.
• Thu 10th Sep '26 · Delisting notice: Nasdaq notified Arcadia on August 31, 2026 that its stockholders' equity of $633,000 is below the $2.5 million minimum for continued listing, giving the company until October 15, 2026 to submit a compliance plan.
• Wed 9th Sep '26 · Going-concern: Arcadia's 10-Q for the quarter ended June 30, 2026 included going-concern language, warning its $4.2 million cash won't cover the next 12 months and it may need to cut spending, sell assets, or pursue bankruptcy without new funding.
• Wed 9th Sep '26 · Earnings: Q2 2026 revenue was $1.443 million (down 1% YoY) with a $6.3 million net loss driven mostly by non-cash valuation charges; cash burn from operations was just $319,000 and the company highlighted rising Zola coconut water sales.
• Wed 9th Sep '26 · Dilution vote: A September 2026 proxy asked holders to approve up to 3,993,296 new shares tied to Series A-1 options from a June 2026 private placement, a potential increase of roughly 161% versus the ~2.4 million shares then outstanding.